Medicinal Plant Research 2025, Vol.15, No.5, 224-232 http://hortherbpublisher.com/index.php/mpr 229 advances facilitate the synthesis of RWE and RCT evidence to capture effectiveness more precisely in more representative clinical practice, especially in the case of multi-component interventions like Astragalus-based treatments (De Lusignan et al., 2015; Selker et al., 2019; Yuan, 2021; Zhuang et al., 2023). 6.2 Assessment of efficacy and safety Efficacy studies of Astragalus in respiratory illness are founded on RCTs as well as real-world data. RCTs demonstrate that Astragalus can add to clinical efficacy such as relief of symptoms, lung function, and health-related quality of life in several diseases of the respiratory tract. Safety profiles are generally good with most trials showing mild or no side effects. However, external validity of RCTs is limited by rigorous inclusion criteria, and more and more is being used in real-world research to determine safety and efficacy in generalizable populations. Robust assessment frameworks now support the combination of evidence from RCTs, systematic reviews, and RWE to provide an overarching view of efficacy and safety (De Lusignan et al., 2015; Blonde et al., 2018). 6.3 Analysis of dosage and treatment duration in clinical applications Dosage and treatment duration analysis is required to enhance Astragalus' clinical use to the maximum. RCTs typically employ standardized doses and predetermined treatment durations, but it could be individualized in real practice based on patient profile and severity of disease. Modern reviews highlight the necessity for better reporting and analysis of dosage and duration in trials to provide guidance and reproducibility. Furthermore, personalized medicine approaches and adaptive clinical trial design are being explored to further individualize Astragalus therapy to a patient's needs, both based on traditional wisdom and modern clinical evidence (Yuan, 2021; Zhuang et al., 2023). 7 Research Challenges and Limitations 7.1 Limited scale and quality of clinical trials Although Astragalus membranaceus is intensively studied for respiratory diseases, a majority of clinical trials are marred with low sample sizes, short intervention durations, and single-center studies. These compromise statistical power, increase the risk of bias, and restrict generalizability of the findings. In addition, variability in study protocols, inclusion criteria of the patient population, and measures of outcome makes it difficult to compare across studies and to perform meta-analyses (Wu et al., 2020; Ying et al., 2021). 7.2 Incomplete understanding of active component mechanisms The major bioactive constituents of A. membranaceus, i.e., polysaccharides, saponins, and flavonoids, exhibit different pharmacological activities such as immunomodulation, anti-inflammation, and antioxidant activity. However, the distinct molecular mechanisms of these effects in respiratory diseases are not well understood. Complex relationships between complex components and targets, and variations in absorption and metabolism, pose significant challenges to mechanism explorations (Shen et al., 2019; Yang and Wang, 2019). 7.3 Limitations in standardized preparations and quality control Clinical action of A. membranaceus can be very dissimilar depending on source, processing, and formulation (Selker et al., 2019; Zhuang et al., 2023). Decoctions, extracts, and injectables differ in the content of bioactive constituents and therefore have disparate effects. Different preparation protocols and details of quality control operations limit reproducibility and pose challenges for clinical application. 7.4 Insufficient translation between clinical and basic research There is a disconnect between mechanistic research and clinical practice. While preclinical studies provide data regarding potential molecular mechanisms and pharmacologic effects, the findings are not always preceded by well-conceived clinical trials with appropriate endpoints. Improved integration of basic science and clinical study design will be necessary for validation of therapeutic mechanisms as well as treatment optimization.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==